Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled α-melanocyte-stimulating hormone analog

Journal of Nuclear Medicine

Volumn 48, Issue 6, 2007, Pages 987-994

  Cheng, Zhen ^a,b   Zhang, Lan ^a,b,c   Graves, Edward ^a,b   Xiong, Zhengming ^a,b   Dandekar, Mangal ^a,b   Chen, Xiaoyuan ^a,b   Gambhir, Sanjiv Sam ^a,b,d  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY   (United States)

^c SHANGHAI INSTITUTE OF APPLIED PHYSICS   (China)

^d Stanford University   (United States)

Author keywords

melanocyte stimulating hormone; 18F; Imaging; Melanoma; PET

Indexed keywords

ACETYLNORLEUCYLASPARTYLHISTIDINE DEXTRO PHENYLALANYLARGINYLTRYPTOPHYLGLLYSYLLYSINAMIDE; ALPHA INTERMEDIN [4 NORLEUCINE, 7 DEXTRO PHENYLALANINE] IODO 2 TYROSINE I 125; ALPHA INTERMEDIN DERIVATIVE; BENZOIC ACID DERIVATIVE; FLUORINE 18; IODINE 125; MELANOCORTIN 1 RECEPTOR; N SUCCINIMIDYL 4 FLUOROBENZOATE F 18; RADIOLIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONJUGATION; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG DISTRIBUTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMAGE ANALYSIS; ISOTOPE LABELING; MELANOMA; MELANOMA B16; MOLECULAR PROBE; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOGRAFT;

ALPHA-MSH; ANIMALS; CELL LINE, TUMOR; FEMALE; FLUORINE RADIOISOTOPES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTOR, MELANOCORTIN, TYPE 1; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 34250333731     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.039602     Document Type: Article

References (37)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet. 2005;365:687-701.
3. Belhocine TZ, Scott AM, Even-Sapir E, Urbain JL, Essner R. Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med. 2006;27:957-967.
4. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231:305-332.
5. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002;2:683-693.
6. Sturm RA. Skin colour and skin cancer: MC1R, the genetic link. Melanoma Res. 2002;12:405-416.
7. Siegrist W, Solca F, Stutz S, et al. Characterization of receptors for alpha-melanocyte-stimulating hormone on human melanoma cells. Cancer Res. 1989;49:6352-6358.
8. Siegrist W, Stutz S, Eberle AN. Homologous and heterologous regulation of alpha-melanocyte-stimulating hormone receptors in human and mouse melanoma cell lines. Cancer Res. 1994;54:2604-2610.
9. 7]-alpha-MSH, an alpha-melanocyte stimulating hormone analogue. Nucl Med Biol. 1997:24:171-178.
10. 99mtechnetium-labeled cyclic alpha-melanocyte- stimulating hormone peptide analogues. Cancer Res. 2000;60:5649-5658.
11. 188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting. Nucl Med Biol. 1999;26:687-693.
12. 111In-labeled DOTA-conjugated rhenium-cyclized alpha-MSH analogues. J Med Chem. 2002;45:3048-3056.
13. 111In-DOTA- rhenium cyclized alpha-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties. J Nucl Med. 2001;42:1847-1855.
14. Froidevaux S, Calame-Christe M, Tanner H, Sumanovski L, Eberle AN. A novel DOTA-alpha-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis. J Nucl Med. 2002;43:1699-1706.
15. Froidevaux S, Calame-Christe M, Tanner H, Eberle AN. Melanoma targeting with DOTA-alpha-melanocyte-stimulating hormone analogs: structural parameters affecting tumor uptake and kidney uptake. J Nucl Med. 2005;46:887-895.
16. 111ln]-DTPA-labeled analogues of alpha-melanocyte-slimulating hormone for melanoma targeling: receplor binding in vitro and in vivo. Int J Cancer. 1994;58:749-755.
17. 7]alpha-melanocyle stimulating hormone. Nucl Med Commun. 1995;16:860-866.
18. Cheng Z, Chen J, Quinn TP, Jurisson SS. Radioiodination of rhenium cyclized alpha-melanocyte-stimulating hormone resulting in enhanced radioactivity localization and retention in melanoma. Cancer Res. 2004;64:1411-1418.
19. Froidevaux S, Calame-Christe M, Schuhmacher J, et al. A gallium-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med. 2004:45:116-123.
20. 11), a cyclized peptide analogue of alpha-MSH. J Med Chem. 2005:48:2985-2992.
21. Cheng Z, Xiong ZM, Wu Y, Zhang X, Chen X, Gumbhir SS. MicroPET imaging of melanoma using Cu-64 labeled alpha-melanocyte stimulating hormone peptide analogue [abstract]. Mol Imaging Biol. 2005:7:126.
22. 64Cu labeled alpha-melanocyte stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem. March 10, 2007 [Epub ahead of print].
23. 188Re-labeled alpha-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J Nucl Med. 2005;46:121-129.
24. Miao Y, Hylarides M, Fisher DR, et al. Melanoma therapy via peptide-targeted α-radiation. Clin Cancer Res. 2005:11:5616-5621.
25. 64Cu-labeled bombesin analogue. Bioconjug Chem. 2003;14:756-763.
26. Boswell CA, Sun X, Niu W, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem. 2004;47:1465-1474.
27. Geissler F, Anderson SK, Venkatesan P, Press O. Intracellular catabolism of radiolabeled anti-μ antibodies by malignant B-cells. Cancer Res. 1992;52:2907-2915.
28. LaBadie JH, Chapman KP, Aronson NN Jr. Glycoprotein catabolism in rat liver: lysosomal digestion of iodinated asiao-fetuin. Biochem J. 1975;152:271-279.
29. Sands H, Jones PL. Methods for the study of the metabolism of radiolabeled monoclonal antibodies by liver and tumor. J Nucl Med. 1987;28:390-398.
30. Shih LB, Thorpe SR, Griffiths GL, et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med. 1994;35:899-908.
31. 18F]FRGD2. J Nucl Med. 2006;47:113-121.
32. 18F-Labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol. 2004;31:179-189.
33. Bullok KE, Gammon ST, Violini S, et al. Permeation peptide conjugates for in vivo molecular imaging applications. Mol Imaging. 2006;5:1-15.
34. Okarvi SM. Recent progress in fluorine-18 labelled peptide radiopharmaceuticals. Eur J Nucl Med. 2001:28:929-938.
35. Okarvi SM. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med Res Rev. 2004:24:357-397.
36. Knight LC. Non-oncologic applications of radiolabeled peptides in nuclear medicine. Q J Nucl Med. 2003;47:279-291.
37. 18F]galacto-RGD. PLoS Med. March 29, 2005 [Epub ahead of print].